Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 181-189 , April 2010

The Utility of Changes in Serum Levels of C-Terminal Telopeptide of Type I Collagen in Predicting Patient Response to Oral Monthly Ibandronate Therapy

Portions of this work have been presented at the following meetings: 7th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Porto, Portugal, March 28–31, 2007; 16th Annual Meeting & Clinical Congress, American Association of Clinical Endocrinologists, Seattle, WA, USA, April 11–15, 2007; 7th International Symposium on Osteoporosis, National Osteoporosis Foundation, Washington, DC, USA, April 18–22, 2007.

  • Marc C. Hochberg

      Affiliations

    • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationAddress correspondence to: Marc C. Hochberg, MD, MPH, Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, 10 S. Pine Street, MSTF 8-34, Baltimore, MD 21201.
    • ,
  • Stuart L. Silverman

      Affiliations

    • Cedars-Sinai/UCLA and OMC Clinical Research Center, Beverly Hills, CA, USA
    • ,
  • Charles E. Barr

      Affiliations

    • Roche, Nutley, NJ, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA

Received 6 May 2009 ,Revised 1 October 2009 ,Accepted 10 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funding sources: This research was funded by Roche.

 Conflicts of interest. Dr. Hochberg has served as a consultant for Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, Roche, and Wyeth. Dr. Silverman has received grants or research support from Lilly, Merck, Novartis, Procter & Gamble, Roche, and Wyeth. and has acted as a consultant or speaker for Amgen, Lilly, GlaxoSmithKline, and Merck. Dr. Barr is an employee of Roche. Dr. Miller has received scientific grants from Procter & Gamble, sanofi-aventis, Roche, Eli Lilly, Merck, Novartis, and Amgen. He has served on speaker boards, advisory boards or as a consultant for Procter & Gamble, sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche, and GlaxoSmithKline.

PII: S1094-6950(10)00008-9

doi: 10.1016/j.jocd.2010.01.007

Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 181-189 , April 2010

Article Tools

* Image Usage & Resolution